Pattern of mutations that results in loss of reduced folate carrier function under antifolate selective pressure augmented by chemical mutagenesis

被引:56
作者
Zhao, RB
Sharina, IG
Goldman, ID
机构
[1] Albert Einstein Coll Med, Albert Einstein Comprehens Canc Ctr, Bronx, NY 10461 USA
[2] Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA
[3] Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA
关键词
D O I
10.1124/mol.56.1.68
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Chemical mutagenesis with N-methyl-N-nitrosourea was employed to study the pattern of mutations in the reduced folate carrier (RFC1) that results in transport-related methotrexate resistance and to identify amino acid residues that ave critical to carrier structure and/or function. Thirty-four methotrexate transport-defective L1210 leukemia cell lines were isolated with folic acid as the sole folate source under antifolate selective pressure. The RFC1 mRNA levels were comparable with, or not substantially decreased, in most of these cell lines relative to wild-type L1210 cells. The molecular basis for the transport defects was investigated by sequencing multiple RFC1 cDNA clones isolated from these mutants by reverse transcription-polymerase chain reaction, which encompassed the entire coding region. The mutations identified were further confirmed either by direct sequencing or, when applicable, by restriction analysis of total reverse transcription-polymerase chain reaction products. The majority of mutations(21) led to single amino acid substitutions that were in, or near, 9 of 12 predicted transmembrane domains, with the highest frequencies in the first, fifth, and eighth. There were no mutations in the sixth, ninth, and twelfth transmembrane domains. Glycine, serine, and arginine were the most frequently mutated residues. These data suggest that several transmembrane domains, rather than the amino- and carboxyl-termini, and the large intracellular loop between the sixth and seventh transmembrane domains play key roles as sites for RFC1 inactivation because ol:single point mutations. This panel of mutated cell lines offers an important resource for studies on RFC1 structure-function and for the evaluation of transport-related cross-resistance patterns with new-generation antifolate inhibitors of tetrahydrofolate cofactor-dependent enzymes.
引用
收藏
页码:68 / 76
页数:9
相关论文
共 40 条
[1]   CHARACTERIZATION OF A MUTATION IN THE REDUCED FOLATE CARRIER IN A TRANSPORT DEFECTIVE L1210 MURINE LEUKEMIA-CELL LINE [J].
BRIGLE, KE ;
SPINELLA, MJ ;
SIERRA, EE ;
GOLDMAN, ID .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (39) :22974-22979
[2]  
CASPARI T, 1994, J BIOL CHEM, V269, P3498
[3]   FUNCTIONAL-ANALYSIS OF THE HIGH-AFFINITY, NA+-DEPENDENT GLUTAMATE TRANSPORTER GLAST-1 BY SITE-DIRECTED MUTAGENESIS [J].
CONRADT, M ;
STOFFEL, W .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (42) :25207-25212
[4]  
COWAN KH, 1984, J BIOL CHEM, V259, P793
[5]  
DIXON KH, 1994, J BIOL CHEM, V269, P17
[6]  
GOLDMAN ID, 1971, ANN NY ACAD SCI, V186, P400
[7]   Defective transport is a common mechanism of acquired methotrexate resistance in acute lymphocytic leukemia and is associated with decreased reduced folate carrier expression [J].
Gorlick, R ;
Goker, E ;
Trippett, T ;
Steinherz, P ;
Elisseyeff, Y ;
Mazumdar, M ;
Flintoff, WF ;
Bertino, JR .
BLOOD, 1997, 89 (03) :1013-1018
[8]   Probing the role of positive residues in the ADP/ATP carrier from yeast. The effect of six arginine mutations on transport and the four ATP versus ADP exchange modes [J].
Heidkamper, D ;
Muller, V ;
Nelson, DR ;
Klingenberg, M .
BIOCHEMISTRY, 1996, 35 (50) :16144-16152
[9]   STRUCTURAL REQUIREMENTS FOR ANION SUBSTRATES OF THE METHOTREXATE TRANSPORT-SYSTEM IN L1210-CELLS [J].
HENDERSON, GB ;
ZEVELY, EM .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1983, 221 (02) :438-446
[10]   Folate-based thymidylate synthase inhibitors as anticancer drugs [J].
Jackman, AL ;
Calvert, AH .
ANNALS OF ONCOLOGY, 1995, 6 (09) :871-881